Aspira Women’s Health Announces Publication of its Second-Generation MultiVariate Index Assay, OVERA®, in the Detection of Cancer in Filipino Women

September 12, 2022

https://www.globenewswire.com/news-release/2022/09/12/2514499/0/en/Aspira-Women-s-Health-Announces-Publication-of-its-Second-Generation-MultiVariate-Index-Assay-OVERA-in-the-Detection-of-Cancer-in-Filipino-Women.html

AUSTIN, Texas, Sept. 12, 2022 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based women’s health company focused on gynecologic disease, today announced publication of a study on the use of its multivariate index assay, MIA2G (OVERA®), in the detection of ovarian cancer in Filipino women in the peer-reviewed International Journal of Environmental Research and Public Health.

Read more at globenewswire.com

Related news for (AWH)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.